Role of IL27 and IL35 as biomarkers and potential targets in acute myeloid leukemia.

e18516 Background: Acute myeloid leukemia (AML) is one of the most common leukemia affecting adult. Regulatory T cells (Tregs) are a subset of CD4 (+) T cells that plays a central role immune tolerance. Objective: We aimed to explore the role of interleukin- 27 (IL27) & interleukin- 35 (IL35) produced by T regs and its associations with clinical characteristics and prognostic markers of AML patients. Methods: The study included 70 patients with acute myeloid leukemia (AML) and 30 healthy controls. We used flowcytometry immunophenotyping to confirm the diagnosis of AML. Serum level of interleukin- 27 (IL 27) & interleukin- 35 (IL 35) were measured at diagnosis by enzyme-linked immunosorbentassay (ELISA). Results: Higher levels of IL27 and IL35 were detected in AML patients than the control group (p ≤ 0.001). We used Receiver operating characteristic (ROC) analysis for detection of optimum IL27 & IL35 cut off level needed for predicting AML. ROC curve analysis demonstrated IL27 optimum cutoff is > 43, AUC 0.926 with a sensitivity 74% and Specificity 96.6% (P-value <0.00). IL35 optimum cutoff was > 27.8 AUC 0.972 with 88% and 98% sensitivity and specificity respectively (P-value <0.001). Serum IL27 & IL35 could well identify AML patients from healthy individuals. More importantly IL27 & IL35 correlated with clinical variable, and could be served as an independent prognostic factor. Conclusions: IL27 & IL 35 might have an application as a diagnostic and prognostic indicator for AML patients and could be served as an independent prognostic factor.